TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Files An 8-K Submission of Matters to a Vote of Security Holders

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 15, 2017, TRACON Pharmaceuticals, Inc. (the Company) held
its Annual Meeting of Stockholders at its corporate headquarters
located at 4350 La Jolla Village Drive, Suite 800, San Diego,
California 92122 at 8:00 a.m. pacific time (the 2017 Annual
Meeting). The Company had 16,583,607 shares of common stock
outstanding and entitled to vote as of April 17, 2017, the record
date for the 2017 Annual Meeting.At the 2017 Annual Meeting,
14,105,614 shares of common stock of the Company were present or
represented by proxy.

At the 2017 Annual Meeting, the Companys stockholders voted on
two proposals, each of which is described in more detail in the
Companys definitive proxy statement on Schedule 14A filed with
the U.S. Securities and Exchange Commission on May 1, 2017.

At the 2017 Annual Meeting, the Companys stockholders:

(1) elected Drs. J. Rainer Twiford and Martin A. Mattingly as
directors of the Company to hold office until the 2020 Annual
Meeting of Stockholders; and

(2) ratified the appointment of Ernst Young LLP as the Companys
independent registered public accounting firm for the fiscal year
ending December 31, 2017.

The following sets forth detailed information regarding the final
certified results of the voting with respect to each matter voted
upon at the 2017 Annual Meeting:

Proposal 1. Election of Directors

Proposal 2. Ratification of the selection of Independent
Registered Public Accounting Firm

About TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company’s lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.